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Genogroup IV and VI Canine Noroviruses Interact with Histo-Blood
Group Antigens
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Imperial College London, St. Mary’s Campus, London, United Kingdomb; INSERM, UMR892, and CNRS, UMR6299, Université de Nantes, Nantes, Francec
ABSTRACT
Human noroviruses (HuNV) are a significant cause of viral gastroenteritis in humans worldwide. HuNV attaches to cell surface
carbohydrate structures known as histo-blood group antigens (HBGAs) prior to internalization, and HBGA polymorphism
among human populations is closely linked to susceptibility to HuNV. Noroviruses are divided into 6 genogroups, with human
strains grouped into genogroups I (GI), II, and IV. Canine norovirus (CNV) is a recently discovered pathogen in dogs, with
strains classified into genogroups IV and VI. Whereas it is known that GI to GIII noroviruses bind to HBGAs and GV norovi-
ruses recognize terminal sialic acid residues, the attachment factors for GIV and GVI noroviruses have not been reported. This
study sought to determine the carbohydrate binding specificity of CNV and to compare it to the binding specificities of norovi-
ruses from other genogroups. A panel of synthetic oligosaccharides were used to assess the binding specificity of CNV virus-like
particles (VLPs) and identified 1,2-fucose as a key attachment factor. CNV VLP binding to canine saliva and tissue samples us-
ing enzyme-linked immunosorbent assays (ELISAs) and immunohistochemistry confirmed that 1,2-fucose-containing H and A
antigens of the HBGA family were recognized by CNV. Phenotyping studies demonstrated expression of these antigens in a pop-
ulation of dogs. The virus-ligand interaction was further characterized using blockade studies, cell lines expressing HBGAs, and
enzymatic removal of candidate carbohydrates from tissue sections. Recognition of HBGAs by CNV provides new insights into
the evolution of noroviruses and raises concerns regarding the potential for zoonotic transmission of CNV to humans.
IMPORTANCE
Infections with human norovirus cause acute gastroenteritis in millions of people each year worldwide. Noroviruses can also
affect nonhuman species and are divided into 6 different groups based on their capsid sequences. Human noroviruses in geno-
groups I and II interact with histo-blood group antigen carbohydrates, bovine noroviruses (genogroup III) interact with alpha-
galactosidase (-Gal) carbohydrates, andmurine norovirus (genogroup V) recognizes sialic acids. The canine-specific strains of
norovirus are grouped into genogroups IV and VI, and this study is the first to characterize which carbohydrate structures they
can recognize. Using canine norovirus virus-like particles, this work shows that representative genogroup IV and VI viruses can
interact with histo-blood group antigens. The binding specificity of canine noroviruses is therefore very similar to that of the
human norovirus strains classified into genogroups I and II. This raises interesting questions about the evolution of noroviruses
and suggests it may be possible for canine norovirus to infect humans.
The family Caliciviridae is a diverse group of single-strandedRNA viruses that can infect a wide range of species. The virus
family is divided into at least five genera, Lagovirus, Vesivirus,
Nebovirus, Sapovirus, and Norovirus, and an additional four gen-
era, Recovirus, Valovirus, Nacovirus, and Bavovirus (1–4), have
been proposed. Caliciviruses can cause a variety of diseases in
animals, including respiratory disease (feline calicivirus), hemor-
rhagic disease (rabbit hemorrhagic disease virus [RHDV]), and
gastroenteritis (noroviruses and sapoviruses). In humans, noro-
viruses are a highly prevalent global pathogen, with up to 18% of
all cases of acute gastroenteritis attributed to human norovirus
(HuNV) in the United Kingdom (5) and 19 to 21 million cases
occurring each year in the United States (6).
Many caliciviruses use carbohydrates as attachment factors to
bind to cells prior to internalization. Murine norovirus (MNV)
and feline calicivirus recognize forms of sialic acids (7, 8), bovine
norovirus binds to alpha-galactosidase (-Gal) (9), and it is also
recognized that a number of caliciviruses bind to specific carbo-
hydrates known as histo-blood group antigens (HBGAs). The La-
govirus RHDV was the first virus identified as using HBGAs as
attachment factors (10), and this was soon followed by the dem-
onstration that human Norwalk virus also uses these carbohy-
drates (11). Subsequent studies showed that the majority, if not
all, of genogroup I (G1) and genogroup II human noroviruses
recognize HBGAs. Most recently, the Tulane virus of the recently
proposed genus Recovirus was also shown to bind these carbohy-
drate structures (12).
HBGAs are terminal structures of glycan chains expressed on
the surfaces of specific cells.HBGAs are foundon red blood cells in
humans and great apes, as well as being located on epithelial cells
of the gastrointestinal, genitourinary, and respiratory tracts in a
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wide variety of species. In addition, HBGAs can be secreted by
these cells into bodily fluids, including saliva (13). The biosynthe-
sis of HBGAs requires the stepwise addition of monosaccharide
units onto glycan chains, a process performed by specific glycosyl-
transferases. HBGAs are derived from different types of precursor
disaccharide structures; the type 1 precursor molecule is a galac-
tose (Gal) joined to an N-acetylglucosamine (GlcNAc) via a 1,3
linkage. Type 2 is Gal1,4GlcNAc. The type 3 precursor is a
Gal1,3GalNAc in linkage to the subjacent structure (i.e., serine
or threonine of the peptide chain), and the type 4 precursor is also
a Gal1,3GalNAc, but in  linkage to the subjacent structure.
Conversion of these structures into the H antigen requires the
action of1,2-fucosyltransferases. On red blood cells and vascular
endothelium, fucosyltransferase 1 (FUT1) is active, whereas in
epithelial cells, FUT2 is active (11). Generation of the Lewis anti-
gens also requires the addition of a fucose, but it is in an 1,3 or
1,4 configuration and requires the activity of either FUT3, FUT4,
FUT5, FUT6, FUT7, or FUT9. Once the H antigens are formed,
biosynthesis can continue by addition of either a GalNAc or a Gal
in 1,3 linkage to give the A or B antigen, respectively. This step is
catalyzed by the A or B enzymes, which are encoded by different
alleles at the ABO locus (13).
Internalization of viral particles into cells occurs following
HuNV attachment toHBGAs in vitro, and hence, the primary step
for HuNV uptake into cells is believed to be HuNV binding to the
HBGAs (11). However, it is worth noting that HBGA expression
alone is not sufficient to enable infection of cells in culture (14),
and at present, there is no cell culture system that allows study of
the full replication cycle of HuNV. Approximately 20% of Cauca-
sians do not express HBGAs on their epithelial cells due to muta-
tions in the FUT2 gene, producing a nonfunctional FUT2 enzyme
(13). Prior to definitive clinical studies, it was hypothesized that
these “nonsecretor” individuals would be resistant to Norwalk
infection (11), and this was later confirmed in two study popula-
tions of 77 and 51 humans, respectively (15, 16).
Canine norovirus (CNV) is a recently discovered member of
the genus Norovirus, first isolated from a dog with gastroenteritis
in Italy in 2007 (17). Evidence for CNV infection has since been
identified in Europe (18–20) and the Far East (21). CNV is be-
lieved to cause gastroenteritis in the canine host, though the virus
has also been isolated from healthy dogs (19, 22). CNV strains
have been assigned to genogroups IV and VI based on the capsid
amino acid sequence. A seventh norovirus genogroup in which
some CNV strains are classified has recently been proposed, but
for this report these particular CNV strains maintain their initial
GVI classification (23). A few rare HuNV genotypes have been
grouped into genogroup IV (24, 25), alongside some of the CNV
strains, although the majority of HuNV strains are classified in
genogroups I and II.
It was predicted that CNV would use carbohydrate structures
to attach to cells prior to infection in a similar manner to many
other caliciviruses investigated to date. The aim of this study was
to identify and characterize the interaction of the virus capsidwith
host cells. Expression of the target carbohydrate was then assessed
in a population of dogs to examine the proportion of the canine
population that may be susceptible to the virus.
MATERIALS AND METHODS
Ethics statement. Human saliva samples were collected as part of a pre-
vious study (26) approved by the Nantes University Hospital Review
Board (study no. BRD02/2-P), with informed written consent obtained
from all saliva donors. Collection of canine saliva samples was a nonregu-
lated procedure, and hence, ethical approval was not required. Canine
gastrointestinal tissue samples were donated by a large pharmaceutical
company. The six dogs had been bred for scientific research but were
deemed unsuitable for the purpose and were humanely euthanized. The
use of rats for antibody generation was approved by the national ethics
review board of the French Ministry of Enseignement Supérieur et de la
Recherche (project license number 01322.01). The animal care and use
protocol adhered to European Directive number 2010/063 and to the
national French regulation (Décret no. 2013-118 du 1er Février 2013
Relatif à la Protection des Animaux Utilisés à des Fins Scientifiques).
Reagents and samples. Anti-CNV polyclonal antibody was generated
by serial inoculation of 2 rats with CNV virus-like particles (VLPs) (Uni-
versity of Nantes, animal experimentation core facility). Recognition of
target VLPs using the antibody generated was confirmed by an enzyme-
linked immunosorbent assay (ELISA).
Canine tissue samples were donated from six healthy 18-month-old
female dogs (labeled A to F) humanely euthanized as surplus to industry
research requirements. Sections of the gastrointestinal tract (1 cm2) were
dissected from the duodenum, jejunum, ileum, cecum, and colon and
placed into 90% ethanol fixative to best preserve the carbohydrate struc-
tures. Samples were then incubated at 4°C for 24 h prior to embedding in
paraffin and sectioning. Additional 1-cm-long sections from the duode-
num, jejunum, ileum, cecum, and colon were dissected, rinsed in phos-
phate-buffered saline (PBS), opened, and scraped into lysis buffer (Gen-
Elute Mammalian Total RNAMiniprep Kit [Sigma-Aldrich]) containing
-mercaptoethanol and guanidinium. The tissue scrapings were homog-
enized and boiled for 10 min prior to storage at 20°C. The mannose-
binding lectin concanavalin A was used to confirm that comparable levels
of carbohydrates were present in all scraping samples.
Canine saliva samples and DNA samples were collected from 23 dogs
at Wood Green Animal Shelter, Huntingdon, United Kingdom (num-
bered 1 to 23), and a further 3 samples were collected from three of the
dogs at a pharmacological research company in the United Kingdom (la-
beled D, E. and F). The dogs at the animal shelter were typically mixed
breeds, whereas the research dogs were beagles. Sample collection was
achieved using a children’s swab (Salimetrics, Newmarket, United King-
dom), from which saliva and buccal cells (for DNA samples) were ex-
tracted. Human saliva samples were collected as part of a previous study
(26).
VLP production.VLPs of three strains of CNV and human norovirus
GI.1 (Norwalk virus) were generated using a previously describedmethod
(18). Recombinant baculoviruses containing VP1 protein from either a
CNV strain or GI.1 were generated, and then, VLPs were produced by
infection ofHi5 insect cells. VLPswere released from the infectedHi5 cells
by three rounds of freeze-thawing and then clarified by removal of cellular
debris (6,000 g; 30 min) and baculovirus (14,000 g for 30 min). The
VLPs were partially purified through a 30% (wt/vol) sucrose cushion in
TNC buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM CaCl2)
containing the protease inhibitor leupeptin at 150,000  g for 2 h. The
pelleted VLPs were resuspended in TNC and further purified by isopynic
centrifugation in cesium chloride (150,000 g; 18 h). The resultant VLP
bands were collected by puncture, and the solution containing VLPs was
dialyzed against PBS prior to quantification by bicinchoninic acid (BCA)
protein assay (Thermo Scientific) and storage at80°C.
ELISA-based microtiter plate assays.NuncMaxisorp immunoplates
were coated with synthetic oligosaccharides as polyacrylamide (PAA) and
human serum albumin (HSA) conjugates (listed in Table 1) at 1 g per
well in 100mMcarbonate buffer, pH 9.6, by overnight incubation at 37°C
in a humidified atmosphere. For assays using saliva and duodenal sam-
ples, immunoplates were coated with the same reagents at a 1:1,000 dilu-
tion under the same conditions.
After overnight coating, and in between all the subsequent incubation
steps, the plates were washed 3 times with 0.05% Tween 20 in phosphate-
Caddy et al.
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buffered saline (PBS-T). The wells were then blocked with 5% milk in
PBS-T for 1 h at 37°C before VLPs (10 g/ml) in 5% milk in PBS-T were
added to each well and incubated for 1 h at 37°C. Rat anti-CNV-VLP
serum at 1/500 dilution in 5%milk in PBS-Twas then added, and another
1-h incubation at 37°C took place. The final 1-h incubation at 37°C was
with horseradish peroxidase (HRP)-conjugated anti-rat IgG (Uptima) at
a 1/10,000 dilution in 5% milk in PBS-T. The enzyme signals were de-
tected using TMB (3,3=,5,5=-tetramethylbenzidine) as the substrate (BD
Bioscience, San Jose, CA), and the reaction was stopped with 1 N phos-
phoric acid. The optical density was read at 450 nm (OD450). To assess the
effect of temperature on VLP binding to synthetic oligosaccharides, a
limited number of experiments were repeated with all incubation steps
at 4°C.
The saliva-phenotyping assay used the ELISA protocol detailed above,
but with the following variations. Following the coating of immunoplates
with saliva samples overnight, A antigen was detected using a mouse
monoclonal anti-A antibody, 2A21, and B antigen was detected using a
specific mouse monoclonal B49 antibody, a B-specific broadly reacting
antibody, as previously described (27). Lewis antigen expression was in-
vestigated using mouse monoclonal antibodies 7-Le, 2.24LE, 3E1, and
12-4. H antigen expression was determined using HRP-conjugated Ulex
europaeus I (Sigma-Aldrich, St. Louis, MO). Secondary HRP-conjugated
anti-mouse (Uptima/Interchim, Montlucon, France) was used for A, B,
and Lewis antigen detection.
1,2-L-Fucosidase (Bifidobacterium bifidum) treatment of duodenal
samples was performed by incubation at 37°C with 10 g fucosidase in
100 mmol/liter sodium phosphate buffer, pH 6.5, for 1 h. Blocking the
wells with 5%milk in PBS-T followed. The enzyme shows exquisite spec-
ificity for 1,2-linked fucose residues (28, 29).
Blocking of VLP binding with synthetic oligosaccharides was achieved
by preincubating 10 g/ml VLPs with 400 g/ml oligosaccharides for 1 h
at 37°C. TheVLPswere then added towells coatedwith duodenal samples,
and the ELISA procedure followed as before.
Sequencing of the canine 1,2-fucosyltransferase gene. Canine
DNA was extracted from the buccal epithelial cells collected with the
Salimetric children’s swab, using a commercial kit (GenElute; Sigma-
Aldrich). Nucleotide sequence alignment of the human 1,2-fucosyl-
transferase (FUT2) gene and the predicted canine Fut2 gene (GenBank
accession number XM_005616863.1) enabled the design of primers to
target the canine Fut2 gene and allowed amplification of the entire gene
for sequencing. The predicted canine Fut2 gene has 87.8% identity with
human FUT2. The primers IGUC0496 (TCCATCCYCCGAGCTAAC)
and IGUC0497 (TCTGTTACTTGCCGCCCAAAGCAT) were used to
amplify a region of DNA 1,020 bp long. Sequencing of PCR products was
performed using primers IGUC0496, IGUC0497, and an additional
primer (GGTACTCCTCCTCCATCCAGTCGT) by the University of
Cambridge Biochemistry DNA-sequencing facility.
Tissue samples and immunohistochemical analysis. Tissue sections
from the gastrointestinal tracts of six dogs were deparaffinized through
baths of LMR-SOL (1-bromopropane,2-methylpropane-2-ol and aceto-
nitrile), followed by rehydration with successive baths of 100, 90, 70, and
50% ethanol. Endogenous peroxidase activity was blocked with 0.3% hy-
drogen peroxide in PBS.Nonspecific bindingwas blockedwith 3%bovine
serum albumin (BSA) in PBS. HRP-conjugated U. europaeus I (Sigma-
Aldrich, St. Louis, MO) at 0.8 g/ml, anti-A monoclonal antibody 2A21,
and anti-B monoclonal antibody B49 were used for binding to H antigen,
A antigen, and B antigen, respectively. Lectins and antibodies were incu-
bated with the tissue sections in 1% BSA in PBS at 4°C (lectin) or 37°C
(antibodies) overnight. After three washes in PBS, a biotinylated anti-
mouse antibody (Vector Laboratories, Burlingame, CA) diluted in 1%
BSA in PBS was added to the assays with primary mouse antibodies. Sec-
tions were washed three times in PBS prior to addition of HRP-conju-
gated avidin D (Vector Laboratories, Burlingame, CA), also diluted in 1%
BSA in PBS. Substrate was added to the slides (AEC kit; Vector Laborato-
ries, Burlingame, CA), followed byMayer’s hematoxylin solution (Merck,
Whitehouse Station, NJ) for contrast staining.
To assess the ability of VLPs to bind to tissue sections, the above-
described protocol was adapted as follows. After sections were blocked
with 3% BSA in PBS, 1 g/ml VLPs was incubated with the sections
overnight at room temperature. Anti-CNV primary antibody was then
incubated with the tissue sections for 1 h at 37°C. After three washes in
PBS, sections were incubated with secondary anti-rat biotinylated anti-
body (Vector Laboratories) for 1 h, and the remainder of the protocol was
completed as previously described. Fucosidase treatment was performed
on some sections after the initial blocking step in 3%BSA by incubation at
TABLE 1 Neoglycoconjugates used to determine the carbohydrate specificities of CNV VLPsa
Name Conjugate Structure
-N-Acetylgalactose PAA GalNAc1
LacNAc PAA Gal1-4GlcNAc1
Forsmann disaccharide PAA GalNAc1-3GalNAc1
H type 1 HSA Fuc1-2Gal1-3GlcNAc1
H type 2 Both Fuc1-2Gal1-4GlcNAc1
H type 3 PAA Fuc1-2Gal1-3GalNAc1
A heptasaccharide HSA GalNAc1-3(Fuc1-2)Gal1-3(Fuc1-4)GlcNAc1-3Gal1-4Glc1
A trisaccharide Both GalNAc1-3(Fuc1-2)Gal1
A disaccharide PAA GalNAc1-3Gal1
A type 2b PAA GalNAc1-3(Fuc1-2)Gal1-4GlcNac1
Lea (Lewis a) PAA Gal1-3(Fuc1-4)GlcNAc1
Leb (Lewis b) Both Fuc1-2Gal1-3(Fuc1-4)GlcNAc1
Lex (Lewis x) PAA Gal1-4(Fuc1-3)GlcNAc1
Ley (Lewis y) Both Fuc1-2Gal1-4(Fuc1-3)GlcNAc1
3-Sulfo Lex PAA HSO3-3Gal1-4(Fuc1-3)GlcNAc1
Sial Lex (sialyl-Lewis x) Both NeuAc2-3Gal1-4 (Fuc1-3)GlcNAc1
Sial Lea (sialyl-Lewis a) Both NeuAc2-3Gal1-4 (Fuc1-3)GlcNAc1
Sialyl LNF V (lacto N-fucopentose V) HSA Fuc1-2Gal1-3(Neu5Ac2-6)GlcNAc1-3Gal1-4Glc 1
Sialyl LNnT (lacto-N-neotetraose) HSA NeuAc2-3Gal1-4GlcNAc1-3Gal1-4Glc1
6-Sulfo sialyl Lex PAA NeuAc2-3Gal1-3(Fuc1-4)(HSO3-6)GlcNAc1
a Twenty-six synthetic oligosaccharides, conjugated to either PAA or HSA, were used in ELISA-based assays to investigate the ability of CNV VLPs to bind carbohydrate structures.
Ten of these synthetic oligosaccharides were only available conjugated to PAA, four were only available conjugated to HSA, and a further six oligosaccharide structures were
available with either PAA or HSA conjugation.
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37°C with 10 g fucosidase in 100 mmol/liter sodium phosphate buffer,
pH 6.5, for a total of 18 h with renewal after 6 h.
Flow cytometry analysis. The binding of norovirus VLPs to cells in
vitrowas assessed usingHT-29 (human colorectal adenocarcinoma cells),
a cell line with well-characterized H antigen and A antigen expression. In
addition, Chinese hamster ovary (CHO) cells transfected with rat 1,2-
fucosyltransferase B cDNA, with or without cotransfection with the rat A
enzyme cDNA or B enzyme cDNA, were utilized. The CHO cells were
generated as part of a previous study (11). A total of 2.5 105 viable cells
were incubated with 10g/ml VLPs in PBS-0.1%BSA for 1 h at 4°C. After
3 washes with the same buffer, a 30-min incubation was performed with
anti-VLP antibody. After washes, a third incubation was performed with
biotinylated anti-rat secondary antibody under the same conditions. The
final incubation step used streptavidin-phycoerythrin (BD Pharmingen).
After final washes in PBS alone, fluorescence analysis was performed on a
FACSCalibur (Becton, Dickinson, Rungis, France) using the CELLQuest
program. Blocking of VLP binding with synthetic oligosaccharides was
achieved by preincubating 10 g/ml VLPs with 400 g/ml oligosaccha-
rides for 1 h at 37°C. Fucosidase treatment of cells was achieved by incu-
bation at 37°Cwith 10g fucosidase in 100mmol/liter sodiumphosphate
buffer, pH 6.5, for 1 h.
RESULTS
Recombinant CNV VLPs bind to synthetic neoglycoconjugates
related toHBGAs. It was hypothesized that CNVwould be able to
bind to cell surface carbohydrates, based on previous studies on
attachment factors for other caliciviruses. Feline calicivirus; rabbit
hemorrhagic disease virus; and human, bovine, and murine no-
roviruses can all recognize cell surface carbohydrates (7–11). To
commence investigations, a panel of immobilized neoglycoconju-
gates were used to assess the ability of CNV to attach to them in
vitro. VLPs of three different strains of CNV were incubated with
a panel of immobilized neoglycoconjugates at 37°C to identify
likely binding partners. The three CNV strains selected for this
study are listed in Table 2. All strains were isolated in 2007, and the
amino acid identities between strains were 58.4% to 60.6%. VLPs
of CNV strain C33 were first tested against an extensive panel of
neoglycoconjugates attached to either PAAorHSA (Fig. 1A). Four
different carbohydrate structures to which VLPs could bind were
identified. TheywereH type 1, A heptasaccharide (A hepta), Lewis
b, and lacto-N-fucopentose. Each of these neoglycoconjugates in-
corporates theH type 1motif Fuc1-2Gal1-3GlcNAc1-R1 (the
structures are shown in Fig. 1A), suggesting that these three car-
bohydrate moieties in the specific H type 1 configuration are im-
portant for CNV binding. This is in agreement with the finding
that, although A heptasaccharide could bind to CNV VLPs, the
closely related A disaccharide (A di) and A trisaccharide (A tri)
neoglycoconjugates could not. A di and A tri neoglycoconjugates
incorporate aGalNAcmoiety, which differentiates A antigen from
H antigen, but they lack GlcNAc, which is one of the three moi-
eties that constitute the H antigen.
All four neoglycoconjugates shown to bindVLPswere attached
to HSA, although there were six additional HSA-conjugated oli-
gosaccharides that did not bind to the VLPs. The conjugate mol-
ecule is suspected to have some effect on the accessibility of the
oligosaccharide, as Lewis b conjugated to PAAwas not able to bind
to the VLPs. This is evidently a limitation of the synthetic neogly-
conjugate binding assay, and subsequent experiments using clin-
ical samples were deemed essential to investigate these binding
preferences further.
Temperature has previously been shown to affect the ability for
norovirus VLP binding to H-type carbohydrates (30), so to inves-
tigate this possibility, synthetic oligosaccharides were incubated
with VLPs at 4°C, and the effect on VLP binding was examined.
Immunoplates were coated with H type 1 (HSA), H type 2 (HSA),
and H type 3 (PAA), and C33 CNV VLPs were added for a 1-h
incubation at 4°C. The results presented in Fig. 1B show that H
type 2 and H type 3 oligosaccharides were able to weakly bind
CNV VLPs at 4°C but showed no ability to bind CNV VLPs at
37°C.
Given the apparent specificity of CNV strain C33 VLP binding
to neoglycoconjugates, it was predicted that the other two CNV
strains available for this study would also behave in a similarman-
ner. To investigate this, strains 170 and HK were incubated with
the 4 neoglycoconjugates shown to bind strain C33 plus a negative
control (A tri). The results shown in Fig. 1D confirmed that at
37°C, all 3 strains of CNV were able to recognize H type 1, A
heptasaccharide, Lewis b, and lacto-N-fucopentose but could not
bind to A tri (which lacks the GlcNAc of the type 1 precursor).
Major capsid protein (VP1) sequence analysis of different
noroviruses. Genogroup I and genogroup II human noroviruses
are known to bind to HBGAs, and following the discovery that
CNVVLPs were able to bind to synthetic HBGA carbohydrates in
vitro, comparison of the major capsid protein amino acid se-
quences was performed. The major capsid proteins of a represen-
tative GI.1 Norwalk virus strain (GenBank accession no.
AAA59229.1) and a GII.4 strain (norovirus Hu/II.4/2201480/HK/
2010; GenBank accession no. ADR78268.1) were aligned with the
three CNV strains (Table 2) using ClustalW. Figure 2 illustrates
only the regions of capsid sequence alignments that incorporate
the amino acid residues shown to interactwithHBGAs in previous
crystallography studies of GI.1 and GII.4 noroviruses (31–33).
Only very limited similarities were identified between the GI.1 or
GII.4 norovirus HBGA-binding amino acids and the capsid se-
quences of the three CNV strains. This suggests that different
mechanisms of carbohydrate binding between CNV and the GI
and GII human noroviruses exist.
Dogs express A, H, and Lewis antigens in their gastrointesti-
nal tracts. To determine if dogs express the carbohydrates identi-
fied as potential CNV attachment factors by the synthetic oligo-
saccharide assay, saliva samples from 26 dogs (1 to 23 and D to F)
and intestinal scrapings from 6 dogs (A to F) were phenotyped
using ELISA-based assays. H antigen carbohydrate was present in
the saliva and intestinal tissue of all the dogs tested (Fig. 3A). These
data were verified by sequencing the complete Fut2 gene of 14 of
these dogs (identified by asterisks in Fig. 3A). The canine Fut2
gene showed high conservation of the nucleotide sequence be-
tween samples, with no evidence of polymorphisms that would
result in an inactive transcript. A single noncoding nucleotide
polymorphism (C777G) was identified in one dog.
Expression ofH antigen along the length of the gastrointestinal
TABLE 2 CNV strains from which VLPs were produced for use in this
study
CNV strain
GenBank
accession
number Abbreviation Genogroup
GIV.2/Bari/170/07-4/ITA EU224456.1 170 IV
C33/Viseu/2007/PRT GQ443611.1 C33 VI
GVI.1/HKU_Ca035F/2007/HKG FJ692501.1 HK VI
Caddy et al.
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tract was examined using samples collected from the duodenum,
jejunum, ileum, cecum, and colon. Concanavalin A was used to
confirm that the amounts of carbohydrate present in all the duo-
denal scrapings were comparable (data not shown). Figure 3B
shows that H antigen expression in the intestines varies between
dogs, but it is apparent that this inversely correlates with A antigen
expression (Fig. 3C).Within the gastrointestinal tract of each dog, H
antigen expression is relatively constant from the duodenum to the
colon. This is in contrast to the H antigen expression patterns re-
ported in humans and in cattle, where expression of the H antigen
diminishes in the distal parts of the gastrointestinal tract (9, 34).
A antigen was shown to be present in 12/26 (46.2%) dogs,
whereas no dogs were B antigen positive. A expression in saliva
correlated with A expression in gastrointestinal secretions, as
demonstrated by phenotyping of saliva samples (D, E, and F) ob-
tained from three dogs from which gastrointestinal tissues were
also available. Of the dogs from which tissues were obtained, two
were identified as being A antigen positive (C and E), and A anti-
gen expression throughout the length of the gastrointestinal tract
in the two animals was relatively constant (Fig. 3C). The A-posi-
tive dogs had comparatively reduced expression of H antigen, as
detected by Ulex binding, which is apparent in Fig. 3B. This is
understood to be due to the ability of the A antigen to mask the H
antigen, thus preventing detection by Ulex lectin binding (27).
Lewis a, Lewis b, and Lewis x were not detectable in canine
saliva or canine gastrointestinal scrapings (data not shown). A lack
of expression of Lewis a and Lewis x antigens was expected based
on previous data that had already confirmedH antigen expression
and therefore secretor status in every dog studied (Fig. 3A). Lewis
y was detectable in 12/26 (46.2%) dogs, although Lewis y antigen
expression was not linked to A antigen expression; dogs could
express both, either, or neither antigen (Fig. 3A). Lewis a and b are
derived from 1,3-fucosyltransferase activity on the type 1 pre-
cursor and H type 1, respectively, whereas Lewis x and y are de-
rived from1,3-fucosyltransferase activity on the type 2 precursor
andH type 2. Among the Lewis y-positive dogs, Lewis y expression
FIG 1 Binding of CNV VLPs to synthetic oligosaccharides. (A and B) CNV strain C33 VLPs were incubated with a panel of 26 neoglycoconjugates at 37°C (A)
and a panel of 5 neoglycoconjugates at 4°C (B) immobilized on immunoplates to determine binding ability. Bound VLPs were detected using an anti-CNV
antibody. Synthetic oligosaccharides were conjugated to either HSA or PAA (unlabeled). An asterisk indicates that the oligosaccharide was available for testing
attached to both types of conjugate, and the mean OD450 for both is presented. VLP binding to Lewis b was significantly different for each conjugate, and hence,
each is shown independently. Schematic structures of the neoglyconjugates recognized by CNV VLPs are presented above the associated bars on the chart. (C)
Neoglycoconjugates shown to bind CNV strain C33 were also incubated with two additional CNV strain VLPs (170 and HK) at 37°C. The error bars represent
standard errors.
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varied significantly, unlike the all-or-nothing expression of A an-
tigen.
CNV VLPs bind to intestinal tissues of A antigen-positive
and -negative dogs. Following identification of putative attach-
ment factors for CNV and the confirmation that expression of
most of these factors is present in the canine intestinal tract, we
examined the ability of CNV VLPs to bind to canine samples.
Immunohistochemistry was used to confirm that CNV VLPs
could bind to canine intestinal sections and also to investigate
the pattern of VLP binding and compare it to carbohydrate
expression. Based on the data obtained using the panel of syn-
thetic neoglycoconjugates, it was hypothesized that CNV bind-
ing would follow H antigen and A antigen expression in the
tissues. Tissue sections from the length of the canine intestinal
tract were incubated with CNV VLPs, and their binding was
detected using primary and secondary antibodies. VLPs from
the three representative strains of CNV (C33, 170, and HK)
were incubated with tissue sections separately, and it was
shown that all the strains were able to bind to the intestinal
tissue sections used in this study (Fig. 4 and data not shown).
Figure 4 shows only data obtained using the CNV strain C33
VLP binding to tissue sections, as it is representative of the two
additional strains (data not shown).
To determine the presence or absence ofH antigen andA antigen
in the tissue sections used for the VLP binding, sections were incu-
bated withUlex and anti-A antigen antibodies, respectively, and im-
munohistochemistry was performed. Both A-positive and A-nega-
tive dogs were compared, as shown in Fig. 4A and B. H antigen
expression was not detectable in the A-positive dogs, in agreement
with the ELISA phenotyping data. Figure 4 demonstrates that CNV
VLPs can bind to both A antigen-positive and A antigen-negative
dogs and that expression of both of these carbohydrates follows a
pattern comparable to that of CNVVLP binding. In particular, VLP
binding closely follows the pattern of A expression when examining
deeper tissues of the pyloric duodenal region (Fig. 4C). VLP binding
was concentrated at the mucosal surfaces of intestinal villi, with no
binding observed in deeper tissues.While this does not prove a direct
association between CNVVLP andHBGA binding, it does add sup-
port to the initial data.
CNVVLP binding ability shows variation related to the car-
bohydrate expression pattern. The phenotyping results demon-
strated that different dogs exhibit variation in carbohydrate ex-
pression comparable to that of most species studied. To
investigate whether this affected the ability of CNV VLPs to bind
to tissues, further assays were required to extend the findings pro-
vided by the initial immunohistochemical studies.
CNV VLPs were incubated with 26 canine saliva samples in an
ELISA-based assay and shown to bind to all of the samples (Fig.
5A). CNV strain C33 was selected as a representative strain for
these experiments, as its binding was more consistent. The OD450
value for the binding of VLPs to each saliva sample was variable,
with a range from 0.076 to 0.784. This variation was compared to
the HBGA phenotype identified in each dog to see if any correla-
tion between binding and expression ofA antigen or Lewis antigen
could be established. Although no statistically significant patterns
were identified, a general trend was seen with regard to samples
that most weakly andmost strongly bound the CNV VLPs. Of the
3 saliva samples that bound the VLPs most weakly (OD450 0.2),
none were A antigen positive. In contrast, all 4 of the saliva sam-
ples that bound to VLPs with an OD450 of 0.7 were A antigen
positive. A significant relationship between Lewis antigen expres-
sion and VLP binding was not identified (data not shown).
As the carbohydrate repertoire of canine saliva samples has, as
far as we are aware, not been characterized, it is likely that carbo-
hydrates are present that were not detected during the phenotyp-
ing studies (Fig. 3) but that contribute to the variation in CNV
VLP binding. In contrast to the paucity of data on carbohydrate
expression in canine saliva, carbohydrate expression in human
saliva is much better characterized. Therefore, it was anticipated
that the use of a comprehensively phenotyped human saliva panel
would providemore conclusive results regarding CNVVLP bind-
ing ability. To this end, 26 human saliva samples representing the
six main groups of HBGA expression patterns known (O Lewis
negative, O Lewis positive, A Lewis negative, A Lewis positive, B
expression, and nonsecretor) were used in ELISA-based assays to
quantitatively study CNV VLP binding. All three CNV strains
available were first incubatedwith a single sample from each of the
six HBGA groups, and identical binding patterns were identified
FIG 2 Alignment of GI.1, GII.4, and CNVmajor capsid protein sequences. Major capsid protein sequences of representative GI.1 (GenBank AAA59229.1) and
GII.4 (GenBank ADR78268.1) human noroviruses and the three CNV strains used in this study were aligned using ClustalW. The 8 (GI.1) and 7 (GII.4) residues
implicated in HBGA binding from crystallographic studies are shaded. Amino acid residues in the three different CNV strain major capsid proteins that are
identical to the key HBGA-binding residues of GI.1 or GII.4 are boxed.
Caddy et al.
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for each strain (Fig. 5B). CNV strain C33 was then selected as a
representative strain for the complete 26-sample panel (Fig. 5C).
Figures 5B andC showed that human saliva samples fromnon-
secretor individuals were not recognized by CNV VLPs. Nonse-
cretors do not have a functional FUT2 gene and hence cannot
express HBGAs on the surfaces of epithelial cells. This confirms
that expression of HBGAs is essential for CNV binding. The single
B antigen-positive saliva sample available in this panel also did not
FIG 3 Phenotyping of canine saliva and gastrointestinal samples using ELISA-based assays. (A) Twenty-six canine saliva samples were analyzed to determine the
expression of H antigen, A antigen, and Lewis y antigen. Saliva samples 1 to 23 were collected from kenneled dogs, whereas samples D, E, and F were collected
from research dogs, from which tissues were also collected. The Fut2 gene was sequenced for 14 dogs, identified by asterisks, in addition to dog B, from which
saliva was not available. (B andC) Phenotyping forH antigen (B) andA antigen (C)was also performed for tissue scrapings from the duodenum, jejunum, ileum,
cecum, and colon of the six dogs A to F. The error bars represent standard errors.
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bind CNV VLP. B antigen expression was confirmed using the
anti-B antibody B49. The structure of the B antigen (Gal1-
3[Fuc1-3]Gal1-GlcNAc1-R1) must therefore preclude bind-
ing, showing that the terminal galactose cannot be accommodated
by the CNV VLP.
Saliva samples containing the O antigen (H antigen) and A anti-
gen, with or without the presence of Lewis antigen, could all bind
CNVVLPs to varying degrees. Excluding nonsecretor andB antigen-
positive samples, the differences between the OD450 values for the
saliva phenotypes were statistically significant (P 	 0.013; one-way
analysis of variance). Figure 5Cdemonstrates that human saliva sam-
ples have an increased ability to bind CNV VLPs if they contain A
antigen and/or Lewis antigen instead of O (H) antigen alone.
To extend these findings further, binding of VLPs to CHO cell
lines transfected with glycosyltransferases was studied using fluo-
rescence-activated cell sorting (FACS) (Fig. 6). CHO cells do not
express 1,2-fucosyltransferase activity and hence are devoid of
ABH antigens (11). Transfection of fucosyltransferase and A or B
enzymes enabled the precise control of ABH antigen expression.
Assessment of human norovirus G1.I VLPs and three strains of
CNV VLPs binding to transfected and untransfected cells was
achieved using FACS. This demonstrated that the GI.1 and CNV
VLPs were able to bind CHO cells expressing H and A antigens,
with a preference for A, but binding to cells expressing B antigen
or no HBGAs at all was substantially less. It is interesting that
HBGA expression of the transfected CHO cells was primarily type
2 structures (unpublished data). Binding of CNV strain C33 VLPs
to type 2 structures at 37°C is contrary to the results obtained with
FIG 4 Immunohistochemical analysis of CNVVLPs binding to canine intestinal tissue sections. VLPswere incubatedwith tissue sections overnight, and binding
was detected using anti-CNV antibody and biotinylated secondary antibody. HBGA expression was determined using anti-A antigen antibody and Ulex lectin.
Binding of either VLPs or antibodies/lectin is indicated by the presence of red signal. (A) Binding of CNV strain C33 to jejunal tissue from an A antigen-negative
dog. (B) C33 binding to jejunal tissue from anA-positive dog. (C) Binding of C33 to tissue from the pyloric duodenal region of the intestine of an A-positive dog.
Caddy et al.
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the synthetic oligosaccharide assay (Fig. 1A), although it does
agree with the data from ELISAs with 4°C incubation steps (Fig.
1B). This indicates that the CNV C33 H antigen specificity is not
absolutely dependent on the1,3 linkage of the Gal-GlcNAcmoi-
ety (H type 1) and can accommodate a 1,4 linkage (H type 2).
Synthetic neoglycoconjugates incubated with VLPs can
block binding to canine samples. To further characterize the ca-
nine carbohydrates involved in recognition of CNVVLPs, a series
of blocking studies were performed. The initial ELISA-based syn-
thetic neoglycoconjugate assays had identified H antigen, A anti-
gen, and Lewis b antigen as likely binding partners of the CNV
VLPs. To investigate the roles of these carbohydrates further, CNV
strain C33 VLPs were preincubated with each synthetic neoglyco-
conjugate prior to addition of the VLPs to either immunoplates
coated with duodenal scrapings (Fig. 7A), cells in tissue culture
(Fig. 7B), or tissue sections (data not shown). Preincubation of
VLPs with H type 1, A hepta (A Lewis b), and Lewis b neoglyco-
conjugates significantly reduced VLP binding to canine duodenal
scrapings (Fig. 7A) and to HBGA-expressing HT-29 cells in tissue
culture (Fig. 7B). In contrast, when VLPs were preincubated with
H type 2,H type 3, andA tri (a truncated formof A antigen lacking
GlcNAc) at 37°C, no reduction in binding to canine samples was
observed.HumannorovirusG1.I VLPswere included in the FACS
studies to provide a comparison set of data for a well-character-
ized norovirus-carbohydrate binding pattern. Overall, these
blockade studies provided further evidence of the importance of
H type 1, A antigen, and Lewis antigen in CNV binding.
Enzymatic removal of specific intestinal carbohydrates re-
duces CNVbinding.Carbohydratemoiety-specific enzymes were
used to cleave off HBGAs shown to play a role in CNV attachment
to the cell surface. 1,2-Fucosidase was incubated with duodenal
scrapings, tissue sections, and cells in tissue culture to remove the
fucosidase of the H antigen (Fig. 8). Fucosidase treatment was
shown to completely abolish CNV VLP binding in A antigen-
negative dogs. In dogs expressing A antigen, however, fucosidase
treatment had no effect on CNV binding to duodenal scrapings
and only amoderate effect on binding to tissue sections. Similarly,
in A antigen-expressing cells used for FACS, no significant change
in CNV VLP binding was observed after fucosidase treatment
(data not shown). From this it can be concluded that inA-negative
dogs, theH antigen is essential for CNVbinding. Fucosidase treat-
ment of A-positive dogs does not result in a change in the binding
pattern because it is understood that the A antigen masks the H
antigen-blocking fucosidase action (27); thus, A antigen will still
be present and sufficient to mediate CNV VLP binding.
DISCUSSION
This study demonstrates that CNV capsid can attach to the H
antigen of the histo-blood group antigen carbohydrates expressed
on the surfaces of epithelial cells. The interaction between the
CNV capsid and the H antigen can accommodate the A antigen
(addition ofN-acetylgalactosamine) and the Lewis antigen (addi-
tion of a 1–3/1-4 fucose) but not the B antigen (addition of
galactose). These conclusions have been drawn from initial assays
using synthetic neoglycoconjugates and CNV VLP binding to in-
testinal sections, saliva, duodenal scrapings, and cells in vitro.
Blocking assays and enzymatic removal of identified carbohy-
drates were then used to confirm these findings. While the merits
of the individual assaysmay be limited (for example, it is predicted
that the conjugate molecules of the neoglyconjugates can affect
VLP binding andmay not be an accurate reflection of the situation
in vivo), the multiple lines of evidence for HBGA binding to CNV
support this overall conclusion.
The discovery that CNV binds to HBGAs was unexpected with
regard to the amino acid sequence of the CNV strains. Compared
FIG 5 CNV VLP binding to canine and human saliva samples. (A) ELISA
plates were coated with 26 canine saliva samples with characterized pheno-
types (A antigen andLewis), and the abilities of CNVVLPs (strainC33) to bind
were assessed. The samples are ordered according to their CNV VLP binding
abilities (low to high). Lewis antigen expression is not shown. (B) Six human
saliva samples, each with a different ABO and Lewis phenotype, were used to
assess binding of CNV VLPs from the three CNV strains available. (C) CNV
strain C33 was next selected as the representative strain to analyze binding to a
wider panel of 26 human saliva samples. Le, Lewis antigen.
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to the Norwalk virus capsid amino acid sequence, there was al-
most no similarity in the amino acids shown to interact with
HBGAs (Asp327, His329, Gln342, Asp344, Trp375, Ser377,
Pro378, and Ser380) (31, 33). When CNV major capsid protein
sequences were compared to those of a GII.4 norovirus, a compa-
rable lack of amino acid identity was observed in the key HBGA-
binding residues (Ser343, Thr344, Arg345, Asp374, Ser441,
Gly442, and Tyr443 [32]). The difference between the amino acid
and HBGA interaction profiles for the genogroup I and geno-
group II noroviruses indicates convergent evolution of the two
genogroups has occurred (35). CNVs have been classified into
GIV and GVI genogroups, genetically distant from the GI and GII
human norovirus strains studied to date. These are the first data to
suggest that norovirus recognition of HBGAsmay have evolved in
at least three different lineages. An alternative explanation for this
finding is the existence of a distant ancestor of all norovirus strains
that evolved the ability to recognize the HBGA carbohydrates that
are conserved among many species. To begin establishing which
proposal is correct, crystallographic studies of the CNV major
capsid protein will be essential to enable identification of amino
acids involved in HBGA recognition.
A limited number of human norovirus strains have been clas-
sified into genogroup IV (24, 25), alongside several of the CNV
strains. The prototype CNV strain was shown to have 69% amino
acid identity to human strains (17), and hence, CNV has been
designated a GIV.2 norovirus while the human strains are GIV.1.
The carbohydrate binding specificities of the human GIV strains
have not been studied. The results from this work suggest that the
human GIV noroviruses may also recognize HBGAs, continuing
the binding specificity identified for previously investigated hu-
man noroviruses. To our knowledge, no human GIV VLPs have
been generated, and hence, production and study of VLPs repre-
sentative of the human GIV strains would be an interesting future
line of investigation.
Identification of H, A, and Lewis antigens as the key ligands for
CNV correlates well with the canine carbohydrate expression phe-
notypes identified in this study. All the dogs tested were positive
for theH antigen, andno inactivatingmutationswere identified in
the canine Fut2 genes sequenced. This is in contrast to FUT2 poly-
morphism in humans, where approximately 1 in 5 Caucasians
have inactivating FUT2 polymorphisms, resulting in the nonse-
cretor phenotype. The polymorphism G428A is responsible for
this phenotype in over 95% of nonsecretors of European and Af-
rican decent, and the A385T polymorphism is predominant in
FIG 6 Binding of CNV and GI.1 VLPs to CHO cells transfected with glycosyltransferases. CHO cells were transfected with rat 1,2-fucosyltransferase B (FTB)
cDNA to induce H antigen expression [CHO-FTB (H)] and were cotransfected with FTB and A enzyme to express A antigen (CHO-A) or transfected with FTB
and B enzyme to express B antigen (CHO-B). CHO cells transfected with the empty PDR2 vector were used as control cells not expressing HBGAs. Binding of
the three CNV strain VLPs (C33, 170, and HK) and GI.1 VLPs to the different cell lines was assessed using FACS. The black lines represent signal in the absence
of VLPs but in the presence of the primary and secondary antibodies. The gray lines represent VLP binding. The number above each histogram is the mean
fluorescence intensity (MFI) (geometric mean).
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Asian nonsecretors (36, 37). In comparison, the single polymor-
phism identified in canine Fut2 was a noncoding mutation, pre-
dicted to be a random change as opposed to a fixed polymor-
phism. Overall, the phenotyping and genotyping data obtained
indicated that nonsecretor individuals were absent from this ca-
nine population. This could be a reflection of the lack of evolu-
tionary pressure to induce resistance alleles.
No dogs were positive for the B antigen, in agreement with two
previous reports examining carbohydrate expression in canine in-
testines (38, 39). A total of 12/26 dogs were positive for the A
antigen, a proportion comparable to that in a 1982 study that
analyzed fucolipid expression in the intestines of 37 dogs and
identified 17 (46%) as A antigen positive (40). The same study
identified Lewis b antigen in 12/37 dogs (32.4%) andLewis a in the
intestines of 8/37 dogs (21.6%). These antigens are derived from
the activity of 1,3-fucosyltransferase on the type 1 precursor and
H type 1 antigen, respectively.Unexpectedly, our results regarding
Lewis antigen expression did not correlate with these previous
data. Lewis a and b expression could not be demonstrated in the
canine saliva or intestinal samples used in this study. This discrep-
ancy might be due to the fact that the 1982 study concerned an
analysis of glycolipids, while in our immunohistochemical ap-
proach, glycolipids are largely removed during the tissue-process-
ing steps. The 1982 study did not consider expression of Lewis x
and y, however, which are generated from the activity of 1,3-
fucosyltransferase on the type 2 precursor andH type 2 antigen. In
our sample population, Lewis y was identified in 12/26 dogs
(46.2%), which is comparable to the level of Lewis b expression
reported in the primary study. Though the precursor antigen is
still questionable, these results confirm that Lewis antigen expres-
sion is present and polymorphic in the canine population. More
extensive phenotyping studies are required to solidify the results
for all types of HBGA expression, but in terms of the ability of
CNV to recognize HBGAs expressed in different dogs, all the dogs
in this study would be potentially susceptible to infection. This
conclusion is supported by recent work from our laboratory,
which identified unexpectedly high seroprevalence to CNV in the
United Kingdom dog population, indicating that the majority of
dogs studied were susceptible to infection (18).
The confirmation that A antigen and Lewis antigen can be
expressed in dogs and that the expression is polymorphic raises
questions regarding the possible biological role of these HBGAs in
the canine population. It has previously been suggested that vari-
ation in cell surface carbohydrate expression could be an evolu-
tionary strategy to avoid having pathogens affect an entire popu-
lation equally (13, 41). The identification of CNV as a pathogen
that can bind to A antigen and Lewis antigen adds support to this
theory for the dog population. It is hypothesized that dogs ex-
pressing these antigens will have altered susceptibility to CNV
infection compared to dogs negative for these antigens. Though
natural CNV in dogs is not believed to produce high mortality
rates (20, 42, 43), it is theorized that a survival advantage may be
FIG 7 Blocking CNV binding to canine samples using synthetic neoglycoconjugates. Neoglycoconjugates were incubated with CNV VLPs for 1 h at 37°C prior
to the VLPs being added to either duodenal scrapings in an ELISA-based assay (A) or human HT29 cells in suspension for FACS (B). Synthetic oligosaccharides
were conjugated to either HSA or PAA, as indicated beneath each bar. The same conjugates were used in the FACS experiments, where the binding of both CNV
strain C33 VLPs and human norovirus GI.1 VLPs was studied. The dashed lines represent signal in the absence of VLPs but in the presence of the primary and
secondary antibodies. The black lines represent VLP binding when VLPs were preincubated with PBS only. The gray lines represent the binding of VLPs to cells
after they had been preincubated with different synthetic oligosaccharides. The number in gray above each histogram is the MFI (geometric mean) of all cells
when VLPs were preincubated with neoglycoconjugate. The second number, in black, for the H type 1 histograms is the MFI of all cells when VLPs were
preincubated with PBS only. The error bars represent standard errors.
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conferred by specific phenotypes, as discussed below. However,
confirmation or refutation of this theory requires a much greater
understanding of the pathology induced by CNV, as well as a
much wider appreciation of carbohydrate polymorphism in dogs.
The range of HBGAs identified as being attachment factors for
CNVwas found to bemost similar to those of GI.1 Norwalk virus.
Norwalk was shown to attach to H type 1 by Marionneau et al.
(11), and subsequent studies identified Lewis b and the A antigen
as additional attachment factors (30, 44, 45). In addition,Norwalk
virus has been shown to bind to H type 2 and H type 3 structures
(11, 30), although the binding has weaker affinity than that of H
type 1 (46). This binding pattern is remarkably similar to that
identified for CNV, and although there appear to be minor varia-
tions between theCNV strains and the degree towhichHBGAs are
recognized, the overall specificities are very similar. The results
from the synthetic oligosaccharide experiments at 4°C and the
FACS data from the glycosyltransferase-transfected CHO cell
studies have demonstrated that CNV can recognize H type 2 and
H type 3 structures, albeit with reduced binding ability in com-
parison with H type 1. Whereas CNV and Norwalk virus HBGA
recognition patterns are highly comparable, HBGA-binding pat-
terns of other human noroviruses are quite distinct from that of
Norwalk virus and thus CNV. For example, GII.5 strains recog-
nize the A and B antigens but not the H antigen, GII.9 strains can
recognize the Lewis a antigen, and GII.4 strains recognize A/B/H
and Lewis antigens (45, 46).
The likely ability of CNV to infect all dogs is in contrast to the
proportion of the human population that are susceptible to GI.1
Norwalk virus. As with CNV, Norwalk virus cannot bind to hu-
man tissues or saliva that do not express HBGAs on epithelial cells
(nonsecretors) (11), and binding to B-positive saliva or red blood
cells is significantly less than for A- orO-positive samples (15, 30).
Consequently, nonsecretors are not susceptible to Norwalk virus
and B-positive humans have a reduced risk of infection (15, 47).
Between 10% and 40% of the human population are B positive,
although this varies geographically (48, 49), and 20% of Cauca-
sians are nonsecretors (11). It has previously been suggested that
noroviruses were initially introduced into humans from nonhu-
man hosts using HBGAs as a common niche (35). The similarities
identified between HBGA recognition of GI Norwalk virus and
CNV are marked. We have established that CNV appears well
adapted to a secretor-positive, B antigen-negative population. An-
imal species other than dogs also exhibit a similar spectrum of
carbohydrate expression; both cattle and pigs do not express B
antigen (9, 50), and no nonsecretor pigs were conclusively identi-
fied in a recent study (51). It is interesting to speculate that GI.1
may have arisen from a norovirus adapted to a B-negative animal
species, such as dogs, which would explain why it lacks this HBGA
specificity. GI.1 infections are now fairly uncommon in the hu-
man population, with GII.4 human norovirus strains dominant
globally. This is believed to be due in part to the ability of GII.4 to
bind to awider range ofHBGAs than any other human strain (52).
GII.4 noroviruses are thus able to recognize a greater proportion
of the human population, outcompeting the norovirus strains
with a narrower host range, such as Norwalk virus (53).
The canine saliva binding studies demonstrated that CNV
VLPs do not bind to all canine samples with equal abilities. This is
despite all dogs expressing H antigen, a primary determinant of
CNV binding, at similar levels. Therefore, our data suggest that
additional factors contribute to the ability of CNV to bind to ca-
FIG 8 Enzymatic treatment of canine samples reduces CNV VLP binding.
Duodenal scrapings and intestinal tissue sections from an A antigen-positive
and an A antigen-negative dog were treated with 1,2--fucosidase or a control
for 1 h (scrapings) or 18 h (tissue sections) at 37°C. The abilities of CNV VLPs
(strain C33) to bind to the scrapings or tissue sections were assessed using an
ELISA-based assay (A) and immunohistochemistry (B), respectively. Confir-
mation that the 1,2--fucosidase removed H antigens was achieved by incu-
bating treated tissue sections with Ulex (Anti-H). The error bars represent
standard errors.
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nine tissues. This in turn suggests that variability in susceptibility
to infection exists in the population. It is suspected that this might
be comparable to the binding and susceptibility patterns identi-
fied for RHDV in rabbits. Like CNV, RHDV is able to bind to
HBGAs and in vitro has been shown to be able to recognize tissue
samples from any rabbit regardless of phenotype. In clinical stud-
ies, however, some rabbit phenotypes are significantly more likely
to become infected than others. It has been demonstrated that this
is viral dose dependent. Certain rabbit phenotypes are susceptible
to very low titers of RHDV, whereas other rabbit phenotypes be-
come infected only if exposed to very high (and thus clinically
rare) viral loads (27). It is predicted that a similar situation might
occur during CNV infection outbreaks. Our data begin to suggest
that A antigen- and Lewis antigen-positive dogs are more likely to
become infected than A-negative dogs, and we speculate that un-
less all phenotypes are exposed to high levels of virus, the A anti-
gen- and Lewis antigen-positive dogs are more susceptible. In our
study population of dogs, 6/26 (23%) were A antigen and Lewis
antigen negative. Recent CNV serology data demonstrated that
approximately 40%of the dogs in aUnited Kingdom group of 173
dogs had not seroconverted, and we hypothesize that this may in
part be due to an A antigen- and Lewis antigen-negative pheno-
type. Testing this hypothesis requires phenotyping dogs identified
with natural CNV infection, which we aim to address in future
work.
Given the close genetic relatedness of CNV to some human
norovirus strains, it has previously been proposed that CNV
could be a zoonotic agent. In a region where CNV was known
to be circulating, serological analysis of veterinarians identified
antibodies to a CNV genogroup VI strain (54). The finding that
CNV recognizes HBGAs common to both dogs and humans
provides some support for this suggestion. The binding exper-
iments conducted as part of this work using human saliva sam-
ples confirm that CNV can attach to carbohydrates present on
human cells and in secretions. This demonstrates that the ini-
tial step required for CNV entry into human cells is present.
However, it should be noted that RHDV can bind to HBGAs (H
type 2, A antigen, and B antigen) (10), and yet there is no
evidence that RDHV can infect humans. HBGA bindingmay be
an initial step in calicivirus-host interaction, but a subsequent
host-restrictive step(s) must be necessary for RHDV infection,
and potentially CNV infection.
In summary, this study has identified HBGAs as the carbohy-
drate attachment factor forCNV strains in both genogroup IV and
genogroup VI. We hypothesize that HBGAs are attachment fac-
tors for other noncanine strains in these genogroups, although
this requires further confirmation. Identification of a third and
fourth genogroup of noroviruses that recognize HBGAs raises key
questions regarding the evolutionary ancestors of these viruses.
Continued investigations into the receptors/coreceptors for the
currently uncharacterized norovirus strains is essential to under-
stand the past and possible future evolutionary directions of this
important viral genus.
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